Meta Platforms Inc. (NASDAQ: META) is one of the While investors continue to question the payoff from Big Tech spending, UBS sees one tech firm showing early signs of monetization.
On June 4, UBS analyst Stephen Ju reiterated a Buy rating and $865.00 price target on Meta Platforms Inc. (NASDAQ: META)
Firm analysts believe that Meta is showing clear signs of GenAI chatbot monetization. “At Conversations 2026, we saw clear signs that Meta is starting to monetize its GenAI-enabled “Business Agent” chatbot.” Hosted by Meta, Conversations 2026 was a major global tech and business messaging conference held on June 3. UBS noted how Meta formally expanded the chatbot’s availability at the conference to businesses of all sizes globally and to Instagram. d8nn / Earlier, the chatbot was limited to beta testing, according to conversations with advertisers. It had also been available in some developing markets but larger markets were untapped.
This broader rollout is an implication that Meta’s GenAI investments can turn into meaningful revenue streams overtime. “The showcase supports our view that Meta remains on track to deliver the largest of its five new GenAI revenue streams and should alleviate investor concerns about its ability to deliver ROIC on its GenAI CapEx.” Analysts noted how investors already expect Meta to spend more on AI in 2027, but that these product launches could also create the potential for 2027 and beyond revenue to start lifting up. While we acknowledge the potential of META as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.